

Global Release of Hemp/Cannabis Genetic Classification and Testing Standards to Reshape Policy and Commerce

VpH and Original Breeders League unveil a scientific framework set to transform hemp and cannabis into a regulated global industry.

WASHINGTON, DC, UNITED STATES, June 19, 2025 /EINPresswire.com/ -- A historic white paper co-authored by VpH and the Original Breeders League (OBL) titled "Hemp/Cannabis Testing



Standard and Genetic Classification: A Framework for Innovation, Regulation, and Economic Growth" is released and now globally available.

This groundbreaking document provides a unified scientific foundation to support regulatory



This white paper represents a turning point—transforming cannabis from a fragmented commodity into a science-based global industry."

Dr. Elias Jackson, SVP, Government & Scientific Affairs, Vyripharm

compliance, enhance therapeutic applications, and accelerate investment in the hemp and cannabis sectors. With pressure mounting globally around THC restrictions and quality control gaps, this paper delivers an actionable roadmap rooted in standardized testing and genetic classification.

Strategic Implications:

The paper proposes a model for governments, businesses, researchers, and health organizations to align on definitions, compliance, and IP protections—paving the

way for scalable trade, improved patient outcomes, and global leadership in cannabinoid science.

VpH, a subsidiary of Vyripharm Enterprises Inc., partnered with OBL, a global steward of genetic integrity, to deliver this timely publication. Together, they address inconsistencies in labeling, lack of reproducibility in research, and mounting regulatory ambiguity.

Stakeholders across the value chain—from cultivators to policymakers—are encouraged to read the white paper and adopt its framework for real-time implementation.

The white paper is now available and can be downloaded directly from the Original Breeders League (https://www.oblintl.com/) or VpH (http://www.vyripharmbio.com) websites. Click the link.

Dr. Elias Jackson VpH, a Subsidiary of Vyripharm Enterprises Inc. email us here Visit us on social media: LinkedIn

This press release can be viewed online at: https://www.einpresswire.com/article/823670849

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2025 Newsmatics Inc. All Right Reserved.